Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia, gastrointestinal stromal tumor, and Philadelphia chromosome‑positive acute lymphoblastic leukemia in appropriate patients.

GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib is a targeted therapy that interferes with specific tyrosine‑kinase driven cancers. - Chronic myeloid leukemia: suppresses BCR‑ABL‑positive leukemic cells and slows disease progression. - Gastrointestinal stromal tumor: inhibits c‑KIT and PDGFR signaling, reducing tumor growth. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: blocks BCR‑ABL activity, improving remission rates.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the lower extremities. - Fatigue: generalized tiredness. - Diarrhea: loose stools. - Muscle cramps: occasional skeletal muscle discomfort.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: reduced left‑ventricular ejection fraction. - Severe neutropenia: marked decrease in neutrophil count increasing infection risk.

Patients should be monitored for known risks and drug‑specific considerations. - Liver function: assess baseline and periodic hepatic enzymes. - Cardiac assessment: evaluate ejection fraction before and during therapy. - Hematology: monitor complete blood count for neutropenia or anemia. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Imatinib may alter the pharmacokinetics of several co‑administered agents.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce imatinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase plasma levels and toxicity.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may lower absorption. - CYP2C8 substrates (e.g., repaglinide): potential increased exposure. - Warfarin: enhanced anticoagulant effect, monitor INR.